mkc1106
Vaccineexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2002 (NCT00033228)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 1
- Kidney Diseases · Phase 1
- Liver Neoplasms · Phase 1
- Melanoma · Phase 2
- Mesothelioma · Phase 1
- Neuroendocrine Tumors · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Diseases · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostate · Phase 1
- Rectal Neoplasms · Phase 1
- Sarcoma · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Stomach Neoplasms · Phase 1
- Testicular Neoplasms · Phase 1
- Thyroid Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mkc1106
- mkc1106-mt
- mkc1106-pp
- mkcc1106-mt
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01026051 | Phase 2 | Oct 1, 2010 | MannKind Corp |
| NCT00688090 | Phase 1 | Jun 1, 2008 | MannKind Corp |
| NCT00423254 | Phase 1 | Feb 1, 2007 | MannKind Corp |
| NCT00033228 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2002 | MannKind Corp |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MannKind Corp | For profit | 4 | 4 | 2 | 2002 |
1 organizations
Page 1 / 1